Protagonist Therapeutics, Inc.
PTGX
$46.28
$0.481.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 624.06% | -- | -- | 36,565.08% | 125.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 624.06% | -- | -- | 36,565.08% | 125.73% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 624.06% | -- | -- | 36,565.08% | 125.73% |
| SG&A Expenses | 29.77% | 32.71% | 27.96% | 33.41% | 5.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.18% | 14.01% | 13.37% | 13.00% | -2.72% |
| Operating Income | 369.98% | 197.32% | 203.43% | 201.64% | 28.71% |
| Income Before Tax | 453.88% | 223.20% | 225.43% | 218.01% | 38.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 448.54% | 221.61% | 223.50% | 215.64% | 38.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 448.54% | 221.61% | 223.50% | 215.64% | 38.02% |
| EBIT | 369.98% | 197.32% | 203.43% | 201.64% | 28.71% |
| EBITDA | 373.72% | 198.58% | 204.81% | 203.02% | 28.90% |
| EPS Basic | 405.40% | 207.96% | 204.11% | 191.97% | 43.46% |
| Normalized Basic EPS | 410.04% | 209.36% | 205.73% | 193.90% | 43.45% |
| EPS Diluted | 382.22% | 201.24% | 197.50% | 185.69% | 42.85% |
| Normalized Diluted EPS | 388.89% | 203.27% | 199.77% | 188.27% | 43.06% |
| Average Basic Shares Outstanding | 8.52% | 13.22% | 17.51% | 19.80% | 15.67% |
| Average Diluted Shares Outstanding | 10.84% | 15.14% | 19.52% | 21.90% | 16.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |